<DOC>
	<DOCNO>NCT02087059</DOCNO>
	<brief_summary>This open-label , multicenter clinical study order collect examine data concern safety efficacy ruxolitinib patient Primary Myelofibrosis ( MF ) , Post-Polycythemia Vera ( PV ) MF , Post-Essential Thrombocythemia ( ET ) MF .</brief_summary>
	<brief_title>A Clinical Study Ruxolitinib Patients With Primary Myelofibrosis ( PM ) , Post-polycythemia Vera ( PV ) Myelofibrosis , Post-essential Thrombocythemia ( ET ) Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>1 . ≥18 year age 2 . Diagnosis PMF , PPVMF , PETMF , regardless JAK2 mutational status . The diagnostic PMF accord World Health Organization ( WHO ) criterion ( Thiele et al. , 2008 ) PPVMF PETMF accord International Working Group Myelofibrosis Research Treatment ( IWGMRT ) criterion ( Barosi et al. , 2008 ) . 3 . At least one risk factor provide definition IWGMRT ( Cervantes et al. , 2009 ; classify intermediate risk1 , intermediate risk2 , high risk ) 4 . Patients intermediate risk1 ( patient one IMGMRT risk factor indicate ) must palpable splenomegaly length ≥5 cm costal margin point great spleen protrusion . 5 . Proportion blast peripheral blood &lt; 10 % 6 . ECOG performance status 0 2 7 . The follow value bone marrow function prior treatment : 1 . Absolute neutrophil count ≥1,000/μL , 2 . Platelet count ≥50,000/μL without administration growth factor , thrombopoietin , platelet transfusion 8 . Stem cell transplantation treatment option present indicate suitable donor . 9 . All drug use treat MF discontinue least 28 day treatment initiation . 10 . Informed consent form sign screening procedure perform 1 . Hepatic renal impairment indicate follow : Direct bilirubin ≥2fold upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) &gt; 2.5fold ULN Creatinine &gt; 2.0 mg/dL 2 . Clinically significant infection bacteria , fungus , mycobacteria , parasite , virus ( screen enrollment postpone completion antibiotic treatment patient acute bacterial infection require antibiotic use ) 3 . Active hepatitis A , B , C HIV infection define positive IgMHA Ab test [ hepatitis A virus antibody ( immunoglobulin M [ IgM ] ) ] , HBs Ag test ( hepatitis B surface antigen ) , HCV Ab test ( hepatitis C virus antibody ) , HIV Ab ( human immunodeficiency virus antibody ) screening . 4 . History malignancy within previous 3 year , except earlystage squamous cell carcinoma basal cell carcinoma . 5 . History serious congenital acquire hemorrhagic disease 6 . Previous platelet count &lt; 25,000/μL absolute neutrophil count &lt; 500/μL , except patient currently undergo treatment myeloproliferative neoplasm cytotoxic therapy reason . 7 . Splenic irradiation within 12 month screen 8 . Administration hematopoietic growth factor receptor agonist ( erythropoietin , granulocyte colony stimulate factor , romiplostim , eltrombopag ) within 14 day screen 28 day treatment initiation . 9 . Currently receive another investigational drug , receive another investigational drug within 30 day start treatment . 10 . History myocardial infarction acute coronary syndrome within 6 month screen 11 . Poorly control unstable angina present 12 . Rapid paroxysmal atrial fibrillation present 13 . Active alcohol drug addiction could hinder patient 's ability comply study 's requirement 14 . Pregnant currently breastfeed woman 15 . Women childbearing potential men reproductive ability unwilling take appropriate contraception measure 16 . Patient concurrent condition , Investigator 's opinion , would jeopardize safety patient compliance protocol 17 . History hypersensitivity study drug drug similar chemical structure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Post-Polycythemia Vera ( PV ) MF</keyword>
	<keyword>Post-Essential Thrombocythemia ( ET ) MF</keyword>
</DOC>